Laronidase

拉罗尼酶

Report date: 2024/06/28 17:23:35
First In Class

Base Information

Drug NameLaronidase
Drug Alias Namelaronidase拉罗尼酶Alpha-L-iduronidaselaronidasumlaronidasa +[12] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionAlpha-L-iduronidase replacements
TargetsDermatan sulfateHeparan sulfateAlpha-L-iduronidase
Therapy Area/IndicationsGaucher's disease type IIIGaucher's disease type IILysosomal Storage Diseases +[11] 
Global Approved IndicationsMucopolysaccharidosis I
Approved Indications in ChinaMucopolysaccharidosis I
Original Approved Country/TerritoryUnited States
Original Approved Date2003/04/30
Country/TerritoryCanadaUnited StatesNetherlands +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBiomarin Pharmaceutical IncGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoBiomarin Pharmaceutical IncSanofi +[5] 
Inactive CompaniesMasonic Cancer Center, University Of MinnesotaUniversity Of California, Los Angeles
Active IndicationsGaucher's disease type IIIGaucher's disease type IIWolman Disease +[9] 
Inactive IndicationsLysosomal Storage DiseasesSpinal Cord Compression

Other Information

ATC CodeA16AB05
Related LinksWikipediaDrugBankKEGG